PMV Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $67.00M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-0.34 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 6, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.40 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | – | $-0.34 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.37 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.02 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.30 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
Press releases
Announcements PMV Pharmaceuticals filed with the SEC
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharma Announces Pricing of Oversubscribed $50Million Public Offering of Securities
Material agreement · Other events · EX-99.1 to Form 8-K
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
Other events · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PYNNACLE Phase 2 Clinical Data Update
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
Agreement terminated · Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Updated PC14586 Phase 1 Data
Other events · EX-99.1 to Form 8-K
KOL Webinar for Phase 1/2 PYNNACLE
Other events · EX-99.2 to Form 8-K
PMV Pharmaceuticals to Present Updated Phase 1 Data on
Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99 to Form 8-K
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
Results of operations · EX-99 to Form 8-K
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a
Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
PMV Pharma Announces Changes to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K